Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Montage of Rare Disease Day contributors: Baroness Nicola Blackwood (Chair Genomics England), Bina Shah (Founder Project 8p), Emily Crossley (CEO, Duchenne UK), Rose and Zeryk Hacking (rare disease family), Gary Lineker OBE (OHCC Ambassador) and Prof. Chas Bountra.
Rare Disease Day contributors: Baroness Nicola Blackwood (Chair Genomics England), Bina Shah (Founder Project 8p), Emily Crossley (CEO, Duchenne UK), Rose and Zeryk Hacking (rare disease family), Gary Lineker OBE (OHCC Ambassador) and Prof. Chas Bountra.

Rare Diseases affect 350 million people worldwide. There are over 7,000 known rare diseases and only 5% have an approved treatment, presenting a major global challenge.

Rare Disease Day is an annual international event raising awareness of rare diseases and their impact on the lives of millions. This year, Oxford hosted a webinar as part of the global virtual event series.  The Oxford-Harrington Rare Disease Centre (OHC), a partnership with the Harrington Discovery Institute in the University’s Department of Paediatrics, brings together Oxford’s significant rare disease expertise across departments.

The OHC hosted a guest lecture by the University’s Pro-Vice Chancellor for Innovation, Prof. Chas Bountra, entitled: Lesson from 2020: Together we can do the impossible, for Rare Disease Day. Highlighting the importance of collaboration, Prof. Bountra talked about how 2020 showed that, with the alignment of stakeholders and resources, what would have taken decades to achieve in the past can now be achieved in months. Years of research and infrastructure development in the University provide the foundations of an effective and rapid response to emerging challenges, whether the COVID pandemic or the global unmet need for rare disease treatments. The Department of Paediatrics hosts Oxford’s COVID-19 vaccine trials, where trials in children have now started.

Baroness Nicola Blackwood offered a message of support. From her own diagnostic journey and with her perspective as Chair of Genomics England, she shared her hope that expansion of genomic sequencing in patients and collaboration with the OHC will deliver much-needed treatments for multiple rare diseases.

Insights from rare disease patients and carers included Gary Lineker OBE, an OHC Ambassador, whose two-month-old son was diagnosed with, and subsequently cured of, a rare blood cancer.

Follow @OHRareDisease to keep up to date with news from The Oxford-Harrington Rare Disease Centre.

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment


Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.